---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-004505"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:07:35.158428+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025

## Summary
- Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.
- Previously untreated high-risk adults: 1-year survival 58%; children: 79% in EAP.
- Refractory patients (failed complement inhibitors): 1-year survival 44% vs historical <20%.
- No safety signals; BLA resubmission expected later Q1 2025, MAA submission by mid-2025.

## SEC filing metadata
- accession: 0001437749-25-004505
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925004505/0001437749-25-004505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925004505/omer20250212_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-004505
- JSON: https://secwatch.observer/filing/0001437749-25-004505.json
- Plain text: https://secwatch.observer/filing/0001437749-25-004505.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.